Compounds 679

Details Compounds 679 Compounds 679

2011-06-21

2011-06-21

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S314000, C546S159000, C546S167000

Reexamination Certificate

active

07964616

ABSTRACT:
The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R1, R2, R3and n are as defined in the specification

REFERENCES:
patent: 3464998 (1969-09-01), Krimmel
patent: 3471491 (1969-10-01), Venkatachala et al.
patent: 4751292 (1988-06-01), Fox
patent: 5643925 (1997-07-01), Naruto et al.
patent: 5804588 (1998-09-01), Dyke et al.
patent: 6949539 (2005-09-01), Alcaraz et al.
patent: 7129246 (2006-10-01), Alcaraz et al.
patent: 7408065 (2008-08-01), Evans et al.
patent: 2001/0003121 (2001-06-01), Baxter et al.
patent: 2004/0236109 (2004-11-01), Van Straten et al.
patent: 2008/0058293 (2008-03-01), Ford et al.
patent: 2008/0058309 (2008-03-01), Cheshire et al.
patent: 2008/0234319 (2008-09-01), Guile et al.
patent: 2009/0143354 (2009-06-01), Evans et al.
patent: 2009/0143428 (2009-06-01), Guile et al.
patent: 650919 (1964-07-01), None
patent: 1943404 (1970-12-01), None
patent: 0002065 (1979-05-01), None
patent: 0501656 (1992-09-01), None
patent: 0867436 (1998-09-01), None
patent: 0940391 (1999-09-01), None
patent: WO95/04720 (1995-02-01), None
patent: WO97/19926 (1997-06-01), None
patent: WO99/26927 (1999-06-01), None
patent: WO99/29660 (1999-06-01), None
patent: WO99/29661 (1999-06-01), None
patent: WO00/61569 (2000-10-01), None
patent: WO00/73283 (2000-12-01), None
patent: WO01/37826 (2001-05-01), None
patent: WO01/94338 (2001-12-01), None
patent: WO03/042190 (2003-05-01), None
patent: WO03/045313 (2003-06-01), None
patent: WO03/080579 (2003-10-01), None
patent: WO03/087037 (2003-10-01), None
patent: 2004106305 (2004-12-01), None
patent: 2005009968 (2005-02-01), None
patent: 2006059945 (2006-06-01), None
Korodi, CA125:275756, abstract only of Het Comm, vol. 2(3), pp. 219-226, 1996.
Hirashima, CA114:201707, abstract only of Nippon Noyaku Gakkaishi, vol. 15(4), pp. 539-551, 1990.
Biggs, J Med Chem, vol. 15(6), pp. 642-646, 1972.
Hirashima, CA 118:56667, abstract only of Com Biochem and Phy, Part C, vol. 103C (2), pp. 321-325, 1992.
Accession No. 2003:42109, CAS Registry No. 487064-48-2, 2003.
Agosta et al., “Preparation of 3-Hydroxycyclohexaneacetonitriles”,J. Org. Chem. 46:4880-4885 (1981).
Alcaraz et al., Preparation of Adamantane Derivatives as P2X7 Receptor Antagonists, CAS Accession No. 2001:904155, 2001.
Alcaraz et al., “Novel P2X7 Receptor Antagonists”Bioorganic and Medicinal Chemistry Letters, 13:4043-4046 (2003).
Author unknown, online article from www.pharmaprojects.com/therapy—analysis/purin—P2X7—0109.htm, Jan. 2009.
Baxter et al., “Hit-to-Lead Studies: The Discovery of Potent Adamantane Amide P2X7 Receptor Antagonists,”Bioorganic and Medicinal Chemistry Letters, 13:4047-4050 (2003).
Bourrie et al., “SSR125329A, A High Affinity Receptor Ligand with Potent Anti-Inflammatory Properties,”Eur. J. of Pharm., 456:123-131 (2002).
Costakis et al., “Synthesis of Some Adamantane Derivatives of 2-Aminobenzothiazoles”,Journal of Medicinal Chemistry14(12):1222-1223 (1971).
Ferrari et al., “Extracellular ATP Triggers IL-1β Release by Activating the Purinergic P2Z Receptor of Human Macrophages”,J. Imtnunol. 159:1451-1458 (1997).
Ferrari et al., “Purinergic Modulation of Interleukin-1β Release from Microglial Cells Stimulated with Bacterial Endotoxin”,J. Exp. Med. 185(3):579-582 (1997).
Fulop et al., “A Versatile Method for the Synthesis ofcis-2-aminomethylcyclanols”Synthetic Communications28(12):2303-2309 (1998).
Henderson et al., “Inhibition of interleukin- 1-induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist”,Cytokine3(3):246-249 (1991).
Ho et al., “Synthesis of a Peptidomimetic Tricyclic Tetrahydrobenzo[ij] quinoline as a VLA-4 Antagonist”,J. Org. Chem. 65:6743-6748, p. 6745, scheme 5, (27) (2000).
Kadota et al., “Significance of IL-1β and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB)”,Clin Exp. Immunol. 103:461-466 (1996).
Khurana et al., “Clinical aspects of rheumatoid arthritis”, Pathophysiology, vol. 12, Issue 3, Abstract (2005).
Kirkham, “Interleukin-1, Immune Activation Pathways, and Different Mechanisms in Osteoarthritis and Rheumatoid Arthritis”,Annals of the Rheumatic Diseases, 50:395-400 (1991).
Leonard et al., “Small Charged Rings. II. The Synthesis of Aziridinium Salts”,J. Am. Chem. Soc. 84:4806-4813 (1962).
Li et al., “Should atherosclerosis be considered a cancer of the vascular wall?”Medical Hypotheses, 64:694-698 (2005).
Mackenzie et al., “Could rheumatoid arthritis have an infectious aetiology?” Drug Discovery Today: Disease Mechanism, vol. 2, Issue 3, Abstract (2005).
Miginiac et al., “Activation of Zinc by Trimethylchlorosilane: An Improved Procedure for the Preparation ofβ-Hydroxy Esters from Ethyl Bromoacetate and Aldehydes or Ketones (Reformatsky Reaction)”,J. Org. Chem. 52:4796-4798 (1987).
Modena et al., “Plant Growth Regulating Activities of 2-[2-(Arylamino)-2-oxoethyl]benzoic acids”,Il Farmaco48(4):567-572 (1993).
Otterness et al., “Possible Role of IL-I in Arthritis: Effects of Prostaglandins in the Regulation of IL-1 Synthesis and Actions”, Agent Act 39 (Suppl):109-120 (1993).
Richards et al., “Substituted 2-Phenyl-benzimidazole Derivatives: Novel Compounds that Suppress Key Markers of Allergy,” Eur. J. of Medic. Chem., 41:950-969 (2006).
Sakito et al., “Interleukin 1β, Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide Therapy”,Respiration63:42-48 (1996).
Sharma et al., “Studies on Fusedβ-Lactams: Synthesis & Antibacterial Activity of Some Pyridyl/Quinoly1-2-azetidinones”,Indian Journal of Chemistry27B:494-497 (1988).
STN International, File REGISTRY, see RN 405068-97-5, 405070-41-9, 405076-22-4, Apr. 14, 2002.
STN International, File REGISTRY, see RN 445032-09-7, Aug. 30, 2002.
STN International, File CHEMCATS, Accession No. 2001:48444, May 14, 2001, NS18552, 2-Quinolinecarboxamide, N-(tricycle[3.3.1.13,7]dec-1-ylmethyl), CAS Registry No. 313688-07-2.
STN International, file CHEMCATS, Accession No. 2002:1977776, Jul. 9, 2002, BAS 1098675, “Cyclopropanecarboxamide, N-(2-methyl-5-quinolinyl)-”, CAS Registry No. 333432-34-1.
STN International, file CHEMCATS, Accession No. Jan. 11, 2001, Cyclopropanecarboxamide, N-(2,6-dimethyl-5-quinoliny1)-(9CI)(CA INDEX NAME), CAS Registry No. 313479-89-9.
STN International, File REGISTRY, see RN 401622-10-4, Mar. 24, 2002.
STN International, File REGISTRY, Registry Copyright Jul. 14, 2006 ACS on STN RN: 892733-99-2,1 page.
STN International, File REGISTRY, Registry Copyright Aug. 8, 2006 ACS on STN RN: 899526-58-0, 1 page.
van den Berg, Lessons from animal models of osteoarthritis,Curr. Opin. Rheumatol, 13(5): 452-6 (2001).
Whitehead et al., “Diuretics. IV. 6-Chloro-3-substituted 7-Sulfamoy1-1,2,4-benzothiadiazine 1,1-Dioxides”,J. Org. Chem. 26:2809-2813 (1961).
Yu et al., “Inhibition of IL-1 Release from Human Monocytes and Suppression of Streptococcal Cell Wall and Adjuvant-induced Arthritis in Rats by an Extract ofTripterygium wilfordiiHook”,Gen. Pharmac. 25(6):1115-1122 (1994).

Affiliated with

Also associated with

Rating

Compounds 679 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds 679, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds 679 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2662035